George E.
- Country
- France
- Department
- N/A
Research Overview
- Phase 3 Randomized Study of Gedatolisib Combination Therapy versus Standard Endocrine Therapy in HR‑Positive, HER2‑Negative Advanced Breast Cancer Post‑CDK4/6 Inhibitor
- Evaluation of Chemotherapy Versus Endocrine Therapy as Second-Line Treatment in ER-Positive HER2-Negative Metastatic Breast Cancer Using Fluoroestradiol F-18
- Evaluation of Reduced Duration of Adjuvant Endocrine Therapy with Exemestane, Anastrozole, and Letrozole in Postmenopausal Women with Low-Risk HR+ HER2- Breast Cancer
Data & Insights
Has run more than one trial at 115 of 376 partner sites.
Specializations
Breast Cancer Subtypes
The investigator specializes in various forms of breast cancer, with particular focus on molecular and receptor-based classifications including triple-negative breast cancer (TNBC), HER2-positive, and hormone receptor-positive (HR+) disease states.
- Early-stage breast cancer management
- Metastatic breast cancer treatment
- Leptomeningeal disease
Therapeutic Approaches
Primary research interests encompass innovative treatment strategies including immunotherapy, targeted therapies, and endocrine therapy. The investigator focuses on personalized treatment approaches based on molecular markers and disease characteristics.
- Neoadjuvant therapy optimization
- CDK4/6 inhibitor combinations
- Anti-HER2 targeted treatments
Precision Medicine
Expertise in biomarker-driven treatment selection and molecular profiling to guide therapeutic decisions. Special interest in circulating tumor DNA (ctDNA) analysis for treatment monitoring and early detection of disease progression.
- ESR1 mutation analysis
- PIK3CA mutation targeting
- Treatment de-escalation strategies
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.